Warburg leads $171m funding in Chinese anti-tumour drug maker HaiHe Biopharma

Source: Volodymyr Hryshchenko/Unsplash

HaiHe Biopharma, a Chinese biopharmaceutical firm that develops innovative anti-tumour drugs, has raised 1.2 billion yuan ($171 million) in a Series B round of financing led by Warburg Pincus.

Other investors who participated in the round include CMB International, a wholly-owned subsidiary of China Merchants Bank (CMB), Legend Capital, a venture capital unit of China’s Legend Holdings, and CICC Capital, the flagship private equity platform of Chinese investment bank CICC.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter